Morgan Stanley Raises PT on Apellis Pharmaceuticals (APLS) to $26, Keeps a Hold Rating

Reported 1 day ago

Writing summary...

You may also interested in these wikis

Baxter International Names ATS’ Hider as Next Chief Executive Officer

Truist Financial Lowers Price Target for AbCellera Biologics to $10 While Maintaining Buy Rating

BRICS Local Currency Initiative: A Long-Delayed Vision

Impact of Trump's Tax Bill on American Healthcare

5 Essential Steps for New Investors from Self-Taught Experts

US Economy Resilient Amid Tariff Challenges

OPEC's Supply Increase Set to Create Oil Surplus and Pressure Prices

The Evolution of Private Credit: Navigating Market Challenges

BridgeBio Pharma Secures $300 Million Through European Royalty Monetization for BEYONTTRA

Jim Cramer Is Optimistic About Domino's Pizza

Back to all Wikis